- Home
- CPRX vs LIVN Comparison
CPRX vs LIVN Comparison
Compare CPRX & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | LIVN |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CPRX | LIVN |
|---|---|---|
| Price | $24.79 | $64.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $35.00 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 897.2K | 771.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $119,072,803.00 | N/A |
| Revenue This Year | $9.20 | $9.43 |
| Revenue Next Year | $10.51 | $6.85 |
| P/E Ratio | $14.75 | ★ N/A |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $32.48 |
| 52 Week High | $26.56 | $71.58 |
Technical Indicators
Market Signals| Indicator | CPRX | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 54.46 |
| Support Level | $22.24 | $61.80 |
| Resistance Level | $24.94 | $65.25 |
| Average True Range (ATR) | 0.66 | 2.00 |
| MACD | 0.18 | 0.29 |
| Stochastic Oscillator | 89.26 | 96.89 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.